Ube Industries and HiLung are teaming up to advance HL001, an experimental therapy to prevent disease progression in idiopathic pulmonary fibrosis (IPF). The companies, both based in Japan, anticipate launching clinical studies of HL001 in people by March 2024. “This most recent agreement solidifies the collaboration between Ube Industries…
News
Healthcare providers involved in diagnosing and treating rare diseases believe that increased physician education and collaboration with specialized facilities will have the greatest positive impact on treating these conditions over the next five years, according to results from a 2021 survey. Definitive Healthcare, a healthcare commercial intelligence company, conducted…
An extract of the plant Lemna minor L., also called duckweed, suppresses the signs and symptoms of idiopathic pulmonary fibrosis (IPF) in disease-induced mice, a study suggests. More research to evaluate dosing and oral availability is recommended, study authors noted. “Pulmonary Protein Oxidation and Oxidative Stress…
Lung Therapeutics’ LTI-03, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF), was safe and well-tolerated in healthy volunteers, with no reports of serious adverse events (side effects) or discontinuations, according to a Phase 1a trial. “We are pleased that LTI-03 has passed this important safety milestone as…
Coenzyme Q10 (CoQ10), an antioxidant found naturally in the body and some foods, may help airway basal stem cells survive and ease symptoms of idiopathic pulmonary fibrosis (IPF), a study in mice given both in a transplant suggests. Researchers observed that more airway basal stem cells, a type of…
The Translational Genomics Research Institute (TGen) will use a big-memory technology, called MemVerge Memory Machine Big Memory virtualization software, to accelerate research on the cellular mechanisms underlying idiopathic pulmonary fibrosis (IPF). “MemVerge Memory Machine has quickly resulted in research value for TGen,” Jonathan Jiang, chief operating officer of…
Trevi Therapeutics announced that CANAL, its proof-of-concept Phase 2 trial evaluating Haduvio (nalbuphine extended-release tablets) for the treatment of chronic cough in people with idiopathic pulmonary fibrosis (IPF) has finished enrolling. The trial (NCT04030026), which is taking place in the U.K., has enrolled about 40 IPF patients…
Patient registries are a hot topic of rare disease research and many organizations are taking advantage of this resource by signing up their patient communities and connecting with researchers. Eric Sid, MD, program officer for the Office of Rare Diseases Research (ORDR), said it is difficult to estimate how…
Problems in the metabolism of low-density lipoprotein (LDL) — also known as “bad cholesterol” — and its receptor contribute to changes in lung cells that ultimately lead to pulmonary fibrosis (PF), an analysis of fibrotic lung tissue and cell and animal models suggests. Notably, a combination of two approved…
Eperisone — an oral muscle relaxant used to treat muscle spasms and rigidity — significantly eased lung scarring and improved lung function in a mouse model of idiopathic pulmonary fibrosis (IPF), a study shows. Comparisons between eperisone and the approved IPF therapies Ofev (nintedanib) and Esbriet (pirfenidone) in…
